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ABSTRACT 22	
This study focused on resolving the relationship between body mass index (BMI) and type 2 23	
diabetes. The availability of multiple variants associated with BMI offers a new chance to resolve 24	
the true causal effect of BMI on T2D, however the properties of these associations and their 25	
validity as genetic instruments need to be considered alongside established and new methods for 26	
undertaking Mendelian randomisation. We explore the potential for pleiotropic genetic variants to 27	
generate bias, revise existing estimates and illustrate value in new analysis methods. A two-28	
sample Mendelian randomisation (MR) approach with 96 genetic variants was employed using 29	
three different analysis methods, two of which (MR-Egger and the weighted median) have been 30	
developed specifically to address problems of invalid instrumental variables. We estimate an odds 31	
ratio for type 2 diabetes per unit increase in BMI (kg/m2) of between 1.19 and 1.38, with the most 32	
stable estimate using all instruments and a weighted median approach (1.26 95%CI (1.17, 1.34)). 33	
TCF7L2(rs7903146) was identified as a complex effect or pleiotropic instrument and removal of 34	
this variant resulted in convergence of causal effect estimates from different causal analysis 35	
methods. This indicated the potential for pleiotropy to affect estimates and differences in 36	
performance of alternative analytical methods. In a real type 2 diabetes focused example, this 37	
study demonstrates the potential impact of invalid instruments on causal effect estimates and the 38	
potential for new approaches to mitigate the bias caused. 39	
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Observational studies have shown body mass index (BMI) to be associated with risk of type 2 40	
diabetes as well as with a range of diabetes-related metabolic traits (1; 2). However, it is well 41	
known that confounding, reverse causation and biases can generate such associations and that 42	
even with careful study design, incorrect inference is possible (3). One approach to circumventing 43	
these problems is to use genetic association results within a Mendelian randomization (MR) 44	
framework (3; 4). In MR analyses, genetic variants act as proxies for an exposure in a manner 45	
independent of confounders. If in addition the variants only affect an outcome of interest through 46	
the chosen exposure, then they are said to be valid instrumental variables (IVs). This enables 47	
evaluation of the causal effect of the exposure on the outcome, escaping some of the limitations of 48	
observational epidemiology; (5). 49	
 50	
Following the success of genome-wide association studies (GWASs), the number of MR analyses 51	
using large numbers of mostly uncharacterized variants associated with complex health outcomes 52	
or intermediates is rapidly increasing (6; 7). In the case of BMI, there are now 97 genetic variants 53	
reliably associated and there are examples where multiple variants have been used as a 54	
composite IV to estimate the causal impact of BMI on health (8). Although using many IVs can 55	
increase the power of MR analyses , it brings with it the concern that enlarged sets of genetic 56	
variants are more likely to contain invalid IVs due to violations of the assumptions necessary for 57	
valid causal inference using traditional methods (9). In particular, horizontal pleiotropy – where a 58	
genetic variant affects the outcome via more than one biological pathway (10) – is a concern. 59	
Importantly, the properties of these associations and their validity as genetic instruments need to 60	
be considered alongside established and new methods for undertaking Mendelian randomisation. 61	
 62	
In response to the general issue of using multiple genetic variants in MR, Bowden et al. (9) 63	
propose both MR-Egger regression, an approach developed from the original Egger regression 64	
technique for assessing small study bias in meta-analysis and a weighted weighted median 65	
approach (11) as alternatives to the standard MR analysis. The MR-Egger and weighted weighted 66	
median approaches both operate using distinct, but critically weaker, versions of the IV 67	
assumptions, and therefore have the potential to deliver robust causal effect estimates. The MR-68	
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Egger method also provides a formal statistical test as to whether or not the average pleiotropic 69	
effect of the genetic variants is equal to zero (9). 70	
 71	
Research Design and Methods 72	
With increasing evidence for multiple biological pathways underlying type 2 diabetes (12; 13) and 73	
increasing numbers of genetic variants available as IVs for BMI, we set out to test the potential for 74	
bias in causal estimates from MR using these state-of-the-art approaches. We compared results 75	
from MR-Egger regression (9) and weighted weighted median (11) approaches to a traditional 76	
inverse-variance weighted (IVW) method (which makes the strong assumption that all variants are 77	
valid IVs) (14) in an investigation of the causal relationship between BMI and type 2 diabetes. 78	
These methods all undertake two-sample Mendelian randomisation whereby the GWAS results for 79	
a disease outcome are unified with those of an exposure of interest and together used to estimate 80	
the causal impact of that exposure on disease. We used published data in a two-sample analysis 81	
strategy taking SNP-exposure and SNP-outcome associations from different sources (15; 16). 82	
 83	
The effect sizes for BMI-associated SNPs with associated standard errors from a mixed-sex cohort 84	
of European ancestry were taken from the Genetic Investigation of ANthropometric Traits (GIANT) 85	
consortium (17) along with results for type 2 diabetes from the DIAbetes Genetics Replication And 86	
Meta-analysis (DIAGRAM) Consortium. To avoid sample overlap, GIANT estimates were re-87	
calculated in the absence of DIAGRAM cohorts yielding a maximum sample size at any given 88	
locus of 189,079. To aid interpretation of the effects of BMI on type 2 diabetes, effect sizes were 89	
transformed to BMI units prior to analysis, assuming one standard deviation (SD) = 4.5kg/m2(17). 90	
For the corresponding SNP-outcome association, we took odds ratios (ORs) and confidence 91	
intervals from a GWAS meta-analysis conducted by the DIAGRAM Consortium. This genome-wide 92	
meta-analysis includes data from 12,171 type 2 diabetes cases and 56,862 controls of mainly 93	
European descent imputed at up to 2.5 million autosomal SNPs (DIAGRAMv3) (18). All but one 94	
(rs4787491, INO80E) of the BMI-associated SNPs (p<5x10-8) from GIANT had results listed in the 95	
DIAGRAMv3 dataset so 96 SNPs with results in both datasets were taken forward for analysis. 96	
 97	
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SNP-exposure and SNP-outcome associations were combined using the three different 98	
approaches outlined above. All analyses were conducted in R 3.2.0 (19). First, an inverse-variance 99	
weighted (IVW) method was implemented to provide a weighted average of the causal effect 100	
estimates (14). This method assumes that all genetic variants (i.e. 100%) satisfy the IV 101	
assumptions (including zero pleiotropy) and uses weights that assume the gene-exposure 102	
association estimates are measured without error (the No Measurement Error (NOME) 103	
assumption).  104	
 105	
Second, we performed MR-Egger regression (9), which assumes NOME but allows each variant to 106	
exhibit pleiotropy. MR-Egger estimates remain consistent only if the magnitude of the gene 107	
exposure associations across all variants are independent of their pleiotropic effects (the InSIDE 108	
assumption) (9). As recommended by Bowden et al (9), the extent to which pleiotropy was 109	
balanced across the set of instruments as a whole was visually assessed by plotting the causal 110	
effect estimates against their precision, using a funnel plot and checking for asymmetry (Figure 111	
1A). The NOME assumption was assessed for MR-Egger via an adaptation of the I2 statistic (!"#$ ) 112	
(20) and adjusted for by combining MR-Egger with the method of Simulation Extrapolation 113	
(SIMEX) (21). Using SIMEX, new data sets are created by simulating gene-exposure association 114	
estimates under increasing violations of NOME and recording the amount of attenuation in the 115	
estimate that occurs. The set of attenuated estimates are then used to extrapolate back to the 116	
estimate that would have been obtained if NOME had been satisfied. 117	
 118	
Finally, a weighted weighted median estimation method was applied (11). The weighted median 119	
provides a consistent estimate of causal effect if at least 50% of the information in the analysis 120	
comes from variants that are valid IVs. For a more detailed description of the three methods 121	
applied, see Online Appendix (Supplementary methods). A leave-one-out permutation analysis 122	
was conducted across all methods to assess the influence of potentially pleiotropic SNPs on the 123	
causal estimates (22). In the case of the linear models (IVW and MR-Egger) two additional 124	
analyses were conducted (23; 24). Firstly, the extent to which the causal estimate from each SNP 125	
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in the set could be considered an outlier was assessed using studentized residuals. Secondly, 126	
Cook’s distance (25) was used as a measure of the aggregate impact of each SNP on the model.  127	
 128	
Results 129	
All three approaches provide evidence of a positive causal relationship between BMI and type 2 130	
diabetes. This is demonstrated in Figure 1B where the slope of the lines show the causal effect 131	
estimates as predicted by the IVW, MR-Egger and m weighted median approaches. Estimates 132	
correspond to an OR for type 2 diabetes per unit increase in BMI (kg/m2) of 1.19, 1.26 and 1.38 for 133	
the IVW, weighted median and MR-Egger analyses, respectively and are in line with a previous 134	
MR estimate of 1.27 (95%CI 1.18, 1.36) (2) (Table 1). Assessment of the NOME assumption with 135	
respect to the MR-Egger estimate gave !"#$ =0.83, suggesting an approximate 15% attenuation of 136	
the causal estimate towards zero. Bias adjustment via SIMEX gave a corrected MR-Egger causal 137	
estimate of 1.46 (95%CI 1.16, 1.84) for type 2 diabetes per unit increase in BMI (kg/m2). 138	
 139	
Considering the individual SNP-based contributions to MR analysis, there is one clear outlier in the 140	
distribution of effects shown in Figure 1 and that is TCF7L2(rs7903146). TCF7L2(rs7903146) 141	
shows an association with BMI that is in the opposite direction to the overall trend (and weak 142	
relative to its effect on type 2 diabetes), resulting in a large negative causal estimate from this SNP 143	
alone. The presence of at least some unbalanced pleiotropy was detected within the set of 144	
variants, as reflected by the intercept estimate of -0.019 (p=0.10) in the MR-Egger analysis.  145	
 146	
To illustrate the impact of TCF7L2(rs7903146) on causal estimates, we performed a sensitivity 147	
analysis in which each SNP in turn was removed from the set in a leave-one-out permutation 148	
analysis. We saw a shift in the causal estimates from the IVW (an increase) and MR-Egger (a 149	
decrease) as a result of the removal of TCF7L2(rs7903146) but no difference in the estimate from 150	
the weighted median approach (Table 1; Figure 2). The results of the leave-one-out permutation 151	
analysis showed that the impact of removing TCF7L2(rs7903146) from the variant set on the IVW 152	
and MR-Egger estimates was greater than that of removing almost any other variant, with the 153	
exception of FTO(rs1558902) (Figure 2A & B). When FTO(rs1558902) was removed, causal 154	
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estimates from both the IVW and MR-Egger analysis decreased (Table 1; Figure 2). In this 155	
instance we also observed movement in the causal effect estimate from the weighted median 156	
(Table 1; Figure 2C). The estimate of the intercept from MR-Egger moved closer to zero following 157	
both the removal of TCF7L2(rs7903146) and FTO(rs1558902) (Figure 2D). TCF7L2(rs7903146) 158	
was also identified as an outlier in both IVW and MR-Egger (studentized residuals, Bonferroni 159	
corrected p<1x10-19) but FTO(rs1558902) was not (Online Appendix (Supplementary Results, 160	
Figures S1A/B)). Calculation of Cook’s distance showed both variants to have a disproportionate 161	
level of influence on the model compared to other variants in the set (Online Appendix 162	
(Supplementary Results, Figures S2A/B)) . 163	
 164	
These results suggest TCF7L2(rs7903146) may be pleiotropic with respect to the outcome, i.e. 165	
that it influences type 2 diabetes through an alternative pathway (other than BMI). Evidence from 166	
existing literature supports this assertion as the type 2 diabetes risk increasing allele at 167	
TCF7L2(rs7903146) has been associated with both increased fasting glucose (26) and decreased 168	
BMI (17). Under the assumption that TCF7L2(rs7903146) demonstrates horizontal pleiotropy with 169	
respect to type 2 diabetes, we would expect its inclusion in the variant set to bias the causal 170	
estimate predicted by the IVW approach, but not that predicted by MR-Egger or the weighted 171	
median. Removing TCF7L2(rs7903146) from the variant set causes a slight shift in the causal 172	
estimates from the IVW and MR-Egger approaches, bringing them more in line with one another 173	
and also with the weighted median estimate which remained stable in this instance. Also of note is 174	
the reduction in the 95% confidence interval of the MR-Egger estimate following removal of the 175	
TCF7L2(rs7903146). This increase in precision following removal of a likely invalid instrument from 176	
the set is another potentially favourable quality of this estimator. The relatively small changes 177	
observed across all methods as a result of removing TCF7L2(rs7903146) are in line with the 178	
relatively weak effect of the SNP as shown in Figure 1B. 179	
 180	
In contrast, the effect of removing FTO(rs1558902) is more noticeable. Regardless of the method 181	
used, removing this variant results in a lower causal estimate (Table 1; Figure 2). The substantial 182	
influence of FTO(rs1558902) was predicable given the strength of its effect relative to the other 183	
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variants (Figure 1B), though properties of this effect are not in line with other variants used to 184	
instrument BMI as reported elsewhere for physical activity (27), thyroid function (28) and 185	
depression (29). The concomitant increase in standard error associated with the estimates here 186	
point towards increased uncertainty moving the estimates towards the null in the absence of 187	
FTO(rs1558902). The weighted median appears robust, even to the removal of FTO(rs1558902), 188	
as demonstrated by the relatively tight distribution of estimates returned from the leave-one-out 189	
permutation analysis (Figure 2C). This is as expected given the tolerance of weighted median 190	
approaches to outliers.  191	
 192	
Discussion 193	
By applying new analytical techniques to an old question – the causal relationship between BMI 194	
and type 2 diabetes – we have explored the potential for invalid instruments to bias causal 195	
estimates in MR. In this case where BMI is the exposure, the opportunity to use a large instrument 196	
list in causal analyses presents both opportunity, through variance explained, but also cost, 197	
through complications generated by instrument properties or methods employed. Results here 198	
suggest that both TCF7L2 and FTO appear to have genetic variation which predicts BMI reliably, 199	
but for which associations with type 2 diabetes do not fully align with that for other variants (given 200	
BMI effects and assumed causality).  201	
 202	
For TCF7L2, only recently suggested to be associated with BMI directly (17), this is not surprising 203	
and reinforces the important point that the validity of a specific method’s MR estimate depends on 204	
whether the genetic variants collectively satisfy its assumptions. In this case, it is possible that the 205	
negative association with BMI observed in GIANT is the product of a form of bias where the risk of 206	
type 2 diabetes is leading to effective treatment, health benefit and BMI reduction. This is 207	
supported by the apparently causal negative relationship between type 2 diabetes and BMI seen in 208	
a reciprocal analysis where BMI is the outcome of interest (Online Appendix (Supplementary 209	
Results, Figure S3)), though is likely to be more a comment on study design than biological effect.  210	
 211	
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In this example, the use of recently derived methods (9; 11) designed to overcome problems 212	
caused by directional pleiotropy, yields estimates which are more stable in the presence or 213	
absence of potentially invalid instruments and confirm the likely magnitude of the average effect of 214	
BMI on type 2 diabetes (i.e. from the most likely and stable estimate, an elevation of odds of 215	
disease of ~26% for each additional unit of BMI). The comparison of results from different methods 216	
for any set of potential instruments is important when assessing the reliability of causal inferences 217	
and important for downstream interpretation. In this case, whilst it is impossible to model precisely, 218	
one can estimate the hypothetical impact of an average population level change in lifecourse BMI 219	
on type 2 diabetes. Given a population size of 64.1 million in the UK in mid 2013(30) and a 220	
modelled prevalence of type 2 diabetes (including non-diagnosed cases) of 7.4%(31; 32), the 221	
estimated reduction in odds for a 1kg/m2 reduction would potentially yield a reduction in the 222	
number of cases from ~4.7-3.6 million (a shift in prevalence to 5.6%). 223	
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Tables 486	
Table 1 – Estimates from the application of inverse-variance weighted, MR-Egger and weighted 487	
median Mendelian randomisation methodologies. Estimates represent the estimated causal effect 488	
of body mass index on type 2 diabetes. 489	
Method  Estimate 95% CI p-value 
Complete variant set (n=96 SNPs) 
IVW  1.20 1.09, 1.30 8.00 x 10-05 
MR-Egger  1.39 1.14, 1.68 1.53 x 10-03 
MR-Egger(α)  -0.019 -0.041, 0.004 0.10 
Weighted median  1.26 1.17, 1.34 5.26 x 10-9 
TCF7L2(rs7903146) removed from the variant set (n=95 SNPs) 
IVW  1.22 1.16, 1.28 1.49 x 10-11 
MR-Egger  1.34 1.17, 1.51 9.71 x 10-06 
MR-Egger(α)  -0.011 -0.024, -0.024  0.13 
Weighted median  1.26 1.19, 1.32 3.29 x 10-10 
FTO(rs1558902) removed from the variant set (n=95 SNPs) 
IVW  1.16 1.06, 1.27 1.31 x 10-03 
MR-Egger  1.30 1.01, 1.65 0.04 
MR-Egger(α)  -0.012 -0.038, 0.014 0.34 
Weighted median  1.21 1.13, 1.28 6.81 x 10-08 
Intercept coefficients MR-Egger(α) represent the average pleiotropic effect of a genetic variant on 490	
type 2 diabetes risk. “IVW” refers to inverse variance weighted estimates, SNP refers to single 491	
nucleotide polymorphism.492	
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Figures 493	
Figure 1 – Genetic associations with body mass index (BMI) and type 2 diabetes from 96 variants measured in GIANT (17) and DIAGRAM (18), 494	
respectively. TCF7L2(rs7903146) and FTO(rs1558902) are marked with a ‘X’ and labelled. 495	
A - funnel plot of minor allele frequency corrected genetic associations with BMI (interpreted as instrument strength) against causal estimates based 496	
on each genetic variant individually, where the causal effect is expressed in logs odds ratio of type 2 diabetes for each unit increase in BMI. The 497	
overall causal estimates (β coefficients) of BMI on type 2 diabetes estimated by inverse-variance weighted (solid black line), MR-Egger (dashed black 498	
line) and weighted median (dotted black line) methods are also shown. Grey solid line represent x=0, that is a causal estimate of zero. 499	
B - scatter plot of genetic associations with type 2 diabetes against associations with BMI, with causal estimates (β coefficients) of BMI on type 2 500	
diabetes estimated by inverse-variance weighted (solid line), MR-Egger (dashed line) and weighted median (dotted line) methods.  501	
 502	
Figure 2 – Distributions of regression estimates resulting from leave-one-out permutation analysis. Solid line = estimate from main analysis (n=96 503	
variants); dashed line = estimate with TCF7L2(rs7903146) removed; dotted line = estimate with FTO(rs1558902) removed. 504	
A - Causal estimates (β coefficients) of BMI on type 2 diabetes estimated by an inverse-variance weighted method 505	
B - Causal estimates (β coefficients) of BMI on type 2 diabetes estimated by MR-Egger 506	
C - Causal estimates (β coefficients) of BMI on type 2 diabetes estimated by a weighted median method 507	
D – Estimates of the intercept by MR-Egger 508	
 509	
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Online Appendix 	
Supplementary methods 
Mendelian randomization framework 
Let Γˆ j  equal the gene-outcome association estimate for variant j = 1, . . ., J, with associated 
standard errorσYj . Let γˆ j  equal the gene-exposure association estimate for variant j, with 
associated standard errorσ Xj . Let the causal effect of the exposure on the outcome be 
denoted by β . An estimate for β  based on variant j alone can be obtained via the ratio 
method as 
ˆ
ˆ
ˆ
j
j
j
β
γ
Γ
=
 
Two forms for the variance of βˆ j are often used: 
(i)  Var(βˆ j ) =
σYj
2
γˆ j
2
  
(ii) Var(βˆ j ) =
σYj
2
γˆ j
2
+
Γˆ j
2σ Xj
2
γˆ j
4
, 
Using either a first order (i) or second order (ii) Taylor series expansion. We use the variance 
from (i). This is equivalent to assuming that the gene-exposure association estimates are 
measured without error and is referred to as the No Measurement Error (NOME) 
assumption.  NOME is equivalent to the assumption !"#$ = 0 for all j, so that  '# = '# for all j. 
 
The inverse variance weighted (IVW) method for the overall causal effect estimate 
Let wj =1/ var(βˆ j )  where var(βˆ j ) is defined as in (i) under NOME. The  inverse variance 
weighted (IVW) estimate for the causal effect is given by the standard meta-analytic formula 
wj
j
∑ βˆ j
w j
j
∑
. 
The (# terms derived under NOME are also referred to as ‘Toby Johnson’ weights. The IVW 
estimate assumes that all genetic variants satisfy the instrumental variable assumptions. If 
this is not true then it could give a biased estimate forβ .The IVW estimate for β   is 
consistent even if all genetic variants are invalid, provided that: 
	 2	
• Across all variants, the magnitude of the gene exposure associations are 
independent of their pleiotropic effects (the InSIDE assumption) 
• NOME is satisfied 
• The pleiotropic effects have zero mean 
The weighted median method for the overall causal effect estimate 
Let βˆ(1) ,…, βˆ(J )  equal the J causal effect estimates ordered from smallest ( βˆ(1) ) to largest (
βˆ(J ) ).  Now define 
w*( j ) =
wj
SJ
,     where    SJ = wj
j
∑ , 
and equate βˆ( j )with a quantile, p( j )
w , defined as  
 p( j )
w =
100
SJ
S( j ) −
w( j )
2
"
#
$$
%
&
'' . 
p( j )
w  represents the quantile from the weighted empirical distribution function of the ordered 
estimates βˆ(1) ,…, βˆ(J ) . The weighted median estimate, βˆWM  is defined as the 50th percentile 
of this weighted distribution. Typically the 50th percentile will lie between two estimates ( βˆ(l )
and βˆ(m) , say), in which case βˆWM is found by linear interpolation. 
βˆWM  is a consistent estimate for β provided that at least 50% of the `weight’ making up SJ  
comes from genetic variants that are valid instruments.  
 
The MR-Egger method for the overall causal effect estimate 
The MR-Egger method performs a weighted linear regression of the gene-outcome 
coefficients on the gene-exposure coefficients: 
 
Γˆ j
σYj
=
β0E
σYj
+β1E
γˆ j
σYj
  
The weights used are also derived under the NOME assumption. If all genetic variants are 
valid instruments, then β0E = 0. The value of βˆ0E  can be interpreted as an estimate of the 
average pleiotropic effect across the genetic variants. An intercept term that differs from zero 
is indicative of overall directional pleiotropy. The MR-Egger estimate forβ , βˆ1E , is consistent 
even if all genetic variants are invalid, provided that: 
• Across all variants, the magnitude of the gene exposure associations are 
independent of their pleiotropic effects (the InSIDE assumption) 
	 3	
• NOME is satisfied. 
If NOME is violated then the MR-Egger estimate of causal effect will be attenuated towards 
the null. We can assess the strength of NOME violation for MR-Egger through the )*"$  
statistic: )*"$ = +,-.+ , where / = 	 12 3425 ,	1 53625 34257789 	and where ' equals the arithmetic mean of 
the '# !:#$  terms . Specifically, the )*"$ 	statistic quantifies the proportion of the total variation 
between the '# !:#$  terms that is due to `true’ variation between the  '# !:#$   terms.  
Consequently, when NOME is satisfied '9, …	 , '7 = '9, … , '7, )*"$  equals 1, and no attenuation 
occurs. When )*"$  = 0.9 we can expect the MR-Egger estimate to be only 90% of its value 
had NOME been satisfied. A crude correction for NOME violation would be  =>?@A65  , however 
this can be unstable as  )*"$  can sometimes be estimated as zero, even when it is truly large. 
We used the established method of Simulation Extrapolation (SIMEX) (1) instead, as 
implemented using the R package simex() (2). Under SIMEX, new data sets are created by 
simulating gene-exposure association estimates under increasing violations of NOME and 
recording the amount of attenuation in the estimate that occurs. The set of attenuated 
estimates are then used to extrapolate back to the estimate that would have been obtained if 
NOME had been satisfied. 
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Supplementary Results 
 
Outlier analysis – Studentized residuals 
 
Figure S1A – Studentised residuals applied to the IVW method. 
 
Figure S1B – Studentised residuals applied to the MR-Egger method.s 
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Outlier analysis – Cook’s distance 
 
Figure S2A – Cook’s distance applied to the IVW method. 
 
Figure S2B – Cook’s distance applied to the MR-Egger method. 
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Figure S3 – MR-Egger analysis of the causal impact of type 2 diabetes on BMI.  
A - scatter plot of genetic associations with BMI against associations with type 2 diabetes, 
with causal estimates (β coefficients) of type 2 diabetes on BMI estimated by inverse-
variance weighted (red line), MR-Egger (blue line) and median-based (green line) methods. 
For this analysis, all 115 confirmed type 2 diabetes associated loci with OR not equal to 1 
from Morris et al (2012)(3) downloaded from DIAGRAM 	http://diagram-
consortium.org/downloads.html) were used. 
A - scatter plot of genetic associations with BMI against associations with type 2 diabetes, 
with causal estimates (β coefficients) of type 2 diabetes on BMI estimated by inverse-
variance weighted (red line), MR-Egger (blue line) and median-based (green line) methods. 
For this analysis, 110 confirmed type 2 diabetes associated loci with OR not equal to 1 and 
no overlapping known BMI loci (excluding FTO, MC4R and TCF7L2) from Morris et al 
(2012)(3) were again used. 
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